Strategic Advisory Board
Seth Orlow, M.D., Ph.D.Dr.
Orlow is Professor of Dermatology, Cell Biology and Pediatrics and
Chairman of New York University (NYU) School of Medicine's Ronald
O. Perelman Department of Dermatology, known worldwide for its
innovative leadership in patient care, education and research. A
graduate of Harvard College and the Albert Einstein College of
Medicine, Dr. Orlow completed his internship and residency
training at Mt. Sinai and Yale. He joined NYU in 1990.
In addition to his background in medicine and science, Dr. Orlow has extensive experience brokering corporate partnerships and in the commercialization of prescription drugs and other products in the dermatology and skin care sectors. He spent nine years as a healthcare venture capitalist and was co-founder of a drug discovery company, Anaderm, which was acquired by Pfizer in 2002.
Paul M. Goldfarb, M.D., F.A.C.S.Dr. Goldfarb is a surgical oncologist who has
been in practice in San Diego since 1980. His practice has focused
on the management of patients with solid tumors. He has extensive
experience in head and neck cancer and has been active in
developing sentinel node biopsy techniques and tumor ablation in
the community. He has been active in the community, having been
President of the American Cancer Society both locally in San Diego
as well as for the state of California and has served on the
National Board of the American Cancer Society. He has also
surveyed the hospital cancer programs for the American College of
Surgeons for five years. His teaching responsibilities through the
university have included working with residents in both plastic
surgery as well as general surgery. In addition to his active
clinical practice, Dr. Goldfarb has also worked on managed health
care programs for CALPERS on their Health Advisory Committee and
as a member of the Board of Governors for the Scripps Health Care
Program Cancer Center.
In addition to his clinical practice, Dr. Goldfarb has been an active consultant in several biotechnology and medical device companies both locally in San Diego as well as nationally. He has also participated in FDA reviews in both the drug and device sections with these companies.
David Darst David Darst joined Rgenix as CEO in 2013 with a mission to develop the world's first cancer therapies designed specifically to target cancer metastasis. Mr. Darst is a former venture capitalist with OrbiMed, where he focused on Venture Capital and PIPE investments in biotechnology, diagnostics, and life science tools companies. Mr. Darst is a co-founder of two biotechnology companies, Potentia Pharmaceuticals and Medicine in Need, with treatments in development for Age-Related Macular Degeneration and Tuberculosis respectively. He also co-founded an internet health company, Firefly Health, and worked as a summer associate with McKinsey & Company, Pfizer, and Millennium Pharmaceuticals. He is a founding investor of Good Start Genetics, and is currently a Director of Apellis Pharmaceuticals and SHC Media, and sits on the Rockefeller Advisory Council and Mount Sinai Icahn Institute Advisory Board. Mr. Darst earned an A.B. degree cum laude from Harvard College and an M.B.A. from Harvard Business School.
Craig Eagle, M.D.Dr.
Eagle joined Pfizer Australia in 2001 as part of the medical
group, where he participated in scientific research, regulatory
strategy and pricing and reimbursement negotiations for compounds
in therapeutic areas including oncology, anti-infectives,
respiratory, arthritis and pain management. He relocated to the
United States in 2003 to fulfill the position of the worldwide
lead for development of celecoxib in oncology to oversee the
global research program. With increasing responsibilities, he
focused primarily on overseeing the global research plans and
teams for irinotecan and dalteparin. In 2007 he became the head of
the oncology therapeutic area global medical group for Pfizer,
which includes the U.S. oncology business. Dr. Eagle, who led the
integration of the Pfizer/Wyeth oncology businesses and portfolio,
has also been involved with teams that resulted in eight new
Following his completion of medical school at the University of New South Wales in Sydney, Australia, Dr. Eagle received his general internist training at Royal North Shore Hospital in Sydney. Dr. Eagle then completed specialist training in hematology/oncology and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA), and he continued to research and develop a new monoclonal antibody at the Royal Prince of Wales Hospital in Sydney.
Ulman is a three-time cancer survivor and nationally recognized
cancer advocate. After overcoming chondrosarcoma and malignant
melanoma twice during his sophomore year in college, Doug and his
family founded the Ulman Cancer Fund for Young Adults, a
non-profit organization to provide support, education, and
resources to young adults, their families and friends who are
affected by cancer. He served as Executive Director of the Ulman
Cancer Fund for four years before joining LIVESTRONG as
director of survivorship in 2001.
Doug has received numerous awards for his leadership and community service. In 2002, Doug was selected from more than 20,000 individuals to appear on more than 15 million boxes of Wheaties Energy Crunch as an American Everyday Hero. In 2003, Doug was selected as the Austin Under-40 award winner in the healthcare category. In 2005, Doug was honored by both the American Psychosocial Oncology Society and the Association of Oncology Social Workers. Most recently Doug was named to the Non-Profit Times Power and Influence Top 50 for 2009, an honor bestowed to the top 50 Non-profit executives.
A frequent guest and contributor on national and local media programs, Doug has been featured on CNN, ABC News, NBC Nightly News, and in The New York Times, The Wall Street Journal, and The Washington Post among many other outlets. Doug also speaks frequently to corporations, civic organizations, schools and Universities covering topics including cancer, philanthropy, grassroots movements, social change, and social media.
Doug currently holds numerous civic and charitable board positions across the country and he just completed serving a four-year term as the Chairman of the National Cancer Institute Director's Consumer Liaison Group. He also sits on the executive board of the Ulman Cancer Fund for Young Adults, and is a founder of the LIVESTRONG Young Adult Alliance among many other board and advisory roles.
Following his three cancer diagnoses, Doug returned to the soccer field and helped Brown University to three Ivy League Championships in four years. He has participated in many marathons, including a 100-mile marathon in the Himalayan Mountains, the New York City and Boston marathons.
Miglani has been with Pfizer Inc. for the last 21 years in
positions of increasing responsibility in Sales, Pricing &
Reimbursement, Market Access, Government Affairs, Communications,
Patient Advocacy, Alliance Development, Medical Advocacy and
External Medical Affairs. In 2000, Bob was instrumental in
creating the Market Access function at Pfizer and heading it for 6
years, bringing the much needed voice of Payers into product
development and commercial strategy.
In the US, Europe and India, Bob has led Pfizer's effort to develop meaningful partnerships to elevate the medical voice in the public health conversation through engaging public health institutions, medical organizations and consumer groups.
Bob is also an accomplished published author of two books as well as a respected voice on US-India business issues as part of his service on the Board of Directors of the Alliance For US-India Business (AUSIB).
An active volunteer, Bob also helps to mentor high school students in underprivileged areas around the world as part of the Albert Schweitzer's Leadership for Life Program.
Joseph M. Chalil, MD, MBA, FACHEDr. Chalil joined Provectus in March 2014 to
serve as a member of the Scientific Advisory Board. Dr. Chalil
currently serves as the Associate Director, Health Science
Executives of Boehringer Ingelheim. He is an expert in US
Healthcare Policy with extensive experience in Pharmaceutical and
In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Chair for the Industry Physician Committee of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past three years. AAPI is the second largest physician organization in the US second only to AMA, and the largest ethnic medical organization in the country.
A veteran of the United States Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems and other healthcare organizations.
Dr. Chalil has also served as an advisor to various national political campaigns on healthcare issues.
He is a winner of multiple awards including BIPI President's Club, Team Excellence Award and AAPI New York president's award for outstanding contribution to US Healthcare. The Asian American Business Development Center, NY has awarded Dr. Chalil the 2013 Outstanding 50 Asian Americans in Business Award. American Association of Cardiologists of Indian Origin (AACIO) recently honored Dr. Chalil for his achievements in the field of Cardiology.
Dr. Chalil holds three US Patents involving usage of sensors inside Human Body in addition to other applications. His research background includes Clinical Trial Management in Cystic Fibrosis, Multiple Myeloma, and publications in American Journal of Respiratory and Critical Care Medicine.
Dr. Chalil completed his higher studies in University of Medicine and Dentistry of New Jersey, Davenport University, JJM Medical College and Baylor College of Medicine. He has been a Visiting Professor at various Universities and serves on various company Boards.
Brendan O'Brien joined Provectus in May 2014 to serve as a member
of the Strategic Advisory Board. Mr. O'Brien is currently VP of
Strategic Planning & Analysis for North American
Pharmaceuticals at Sanofi. In this role, he is responsible for
business planning and strategy development; he leads both the
three-year strategic planning and one-year operating planning
processes for Sanofi US, the North American affiliate of Sanofi
Mr. O'Brien started his career in healthcare, working for ten years in sales, marketing and planning for managed care organizations in the Pacific Northwest. In 1998, he moved on to work in pharmaceuticals at Smithkline Beecham Pharmaceuticals in London, UK where he directed development of strategic plans for 14 European markets. From there, Mr. O'Brien went to Pfizer spending the next 13 years in roles with increasing levels of management responsibility in many European countries, including managing director/general manager of Pfizer's country organizations in both Slovakia and Romania.
Mr. O'Brien received his B.A. degree cum laude from Bowdoin College in Brunswick, ME, and he holds a Master's degree in Business Administration from London Business School in London, UK.
Jacob M. Plotsker
Mr. Plotsker is currently Director of IUS Strategy and Lifecycle
Management at Bayer Healthcare. Jacob started his career as a
staff accountant at Deloitte & Touche. He started his career
in the pharmaceutical industry in 1990 when he joined Pfizer,
where over the next 16 years he held roles of increasing
responsibility in the Finance and Marketing functions. He
subsequently moved to Organon BioSciences/Schering Plough as
Senior Director of US and Global Marketing. From 2009 to 2012, he
worked for Teva Pharmaceuticals as Head of Marketing and Senior
Director, Commercial Operations in the branded Women's Health
Mr. Plotsker currently serves on the board of directors of Emisphere Technologies, a publicly traded drug delivery technology company. From 2008 to 2014, he served on the board of directors of Sharsheret, a national 501(c)(3) not-for-profit organization providing support and resources to young women living with breast cancer. He served as President of Sharsheret from 2009-2012.
He holds a BA from Queens College of the City University of New York, an MBA from the Stern School of Business at New York University, and completed the Executive Program in General Management at the University of Chicago's Booth School of Business.
Scientific Advisory Board
Kelly M. McMasters, M.D., Ph.D. Dr. McMasters joined Provectus in June 2008
to serve as a member of the corporate Board of Directors and head
of the Scientific Advisory Board.
Dr. McMasters received his undergraduate training at Colgate University prior to completing the MD/PhD program at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School and Rutgers University. He then completed the residency program in General Surgery at the University of Louisville, and a fellowship in Surgical Oncology at M.D. Anderson Cancer Center in Houston. He is currently the Sam and Lolita Weakley Professor of Surgical Oncology at the University of Louisville in Kentucky, a position he has held since 1996. Since 2005, he has chaired the Department of Surgery at the University of Louisville and also has been Chief of Surgery at University of Louisville Hospital. Since 2000, he has also been Director of the Multidisciplinary Melanoma Clinic of the James Graham Brown Cancer Center at the University of Louisville. His is an active member of the surgery staff at the University of Louisville Hospital, Norton Hospital and Jewish Hospital in Louisville. He is on the editorial boards of the Annals of Surgical Oncology, Cancer Therapy and the Journal of Clinical Oncology as well as an ad hoc reviewer for 9 other publications. He holds several honors, chief among them is "Physician of the Year" awarded by the Kentucky Chapter of the American Cancer Society. He is the author and principal investigator (PI) of the Sunbelt Melanoma Trial, a multi-institutional study involving 3500 patients from 79 institutions across North America and one of the largest prospective melanoma studies ever performed. He has been a PI, Co-PI or local PI in over thirty clinical trials ranging from Phase 1 to Phase 3. For the past 12 years he has also directed a basic and translational science laboratory studying adenovirus-mediated cancer gene therapy funded by the American Cancer Society and the National Institutes of Health (NIH). He was also on the Scientific Advisory Board of Veridex, LLC..
(c) 2002-2014 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.